Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | — |
he has some mobility issues; Sick; This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (he has some mobility issues) and ILLNESS (Sick) in a male patient of an unknown age who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) for COVID-19 prophylaxis. Previously administered products included for Product used for unknown indication: Pfizer COVID-19 Vaccine (in the past always had Pfizer.). Past adverse reactions to the above products included No adverse effect with Pfizer COVID-19 Vaccine. Concurrent medical conditions included CLL (lymphoma (CLL)) and Mobility decreased. On an unknown date, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (unknown route) 1 dosage form. In August 2024, the patient experienced ILLNESS (Sick). On an unknown date, the patient experienced MOBILITY DECREASED (he has some mobility issues). At the time of the report, MOBILITY DECREASED (he has some mobility issues) was resolving and ILLNESS (Sick) outcome was unknown. The action taken with mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Unknown) was unknown. Concomitant medication was not provided. It was reported that the patient had been sick in august and had some mobility issues as well as lymphoma (CLL) which he was taking unspecified medication for and was controlled. It was unknown if the patient experienced any additional symptoms or events. This case was linked to US-MODERNATX, INC.-MOD-2025-789702 (E2B Linked Report).; Sender's Comments: US-MODERNATX, INC.-MOD-2025-789702:Master case
Medical History/Concurrent Conditions: CLL (lymphoma (CLL)); Mobility decreased